@article {Cai2020.02.22.20026617, author = {Xue-fei Cai and Juan Chen and Jie-li Hu and Quan-xin Long and Hai-jun Deng and Kai Fan and Pu Liao and Bei-zhong Liu and Gui-cheng Wu and Yao-kai Chen and Zhi-jie Li and Kun Wang and Xiao-li Zhang and Wen-guang Tian and Jiang-lin Xiang and Hong-xin Du and Jing Wang and Yuan Hu and Ni Tang and Yong Lin and Ji-hua Ren and Lu-yi Huang and Jie Wei and Chun-yang Gan and Yan-meng Chen and Qing-zhu Gao and A-mei Chen and Chang-long He and Dao-Xin Wang and Peng Hu and Fa-Chun Zhou and Ai-long Huang and Ping Liu and De-qiang Wang}, title = {A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease 2019 (COVID-19)}, elocation-id = {2020.02.22.20026617}, year = {2020}, doi = {10.1101/2020.02.22.20026617}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {A respiratory illness has been spreading rapidly in China, since its outbreak in Wuhan city, Hubei province in December 2019. The illness was caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical manifestations related to SARS-CoV-2 infection ranged from no symptom to fatal pneumonia. World Health Organization (WHO) named the diseases associated with SARS-CoV-2 infection as COVID-19. Real time RT-PCR is the only laboratory test available till now to confirm the infection. However, the accuracy of real time RT-PCR depends on many factors, including sampling location and of methods, quality of RNA extraction and training of operators etc.. Variations in these factors might significantly lower the sensitivity of the detection. We developed a peptide-based luminescent immunoassay to detect IgG and IgM. Cut-off value of this assay was determined by the detection of 200 healthy sera and 167 sera from patients infected with other pathogens than SARS-CoV-2. To evaluate the performance of this assay, we detected IgG and IgM in the 276 sera from confirmed patients. The positive rate of IgG and IgM were 71.4\% (197/276) and 57.2\% (158/276) respectively. By combining with real time RT-PCR detection, this assay might help to enhance the accuracy of diagnosis of SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Emergency Project from the Science \& Technology Commission of Chongqing; The Major National S\&T program grant (2017ZX10202203 and 2017ZX10302201) from Science \& Technology Commission of China; The grant (81871635, 81671997 and 81902060) from the National Natural Science Foundation of China, and the grant (20180141 and 20170413) from the Science \& Technology Commission of Yuzhong district, Chongqing.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the paper}, URL = {https://www.medrxiv.org/content/early/2020/02/25/2020.02.22.20026617}, eprint = {https://www.medrxiv.org/content/early/2020/02/25/2020.02.22.20026617.full.pdf}, journal = {medRxiv} }